CLINICAL STUDIES
Improved left ventricular endocardial border delineation and opacification with OPTISON (FS069), a new echocardiographic contrast agent
Results of a phase III multicenter trial1
Jerald L. Cohen, MD, FACC*,
Jorge Cheirif, MD, FACC ,
Douglas S. Segar, MD, FACC ,
Linda D. Gillam, MD, FACC ,
John S. Gottdiener, MD, FACC||,
Eva Hausnerova, MD|| and
Denise E. Bruns, BS¶
* New Jersey VA Medical Center, East Orange, New Jersey, USA
Ochsner Clinic, New Orleans, Louisiana, USA
Krannert Institute of Cardiology, Indianapolis, Indiana, USA
Hartford Hospital, Hartford, Connecticut, USA
|| Georgetown University Medical Center, Washington, D.C., USA
¶ Molecular Biosystems, Inc., San Diego, California, USA
Manuscript received November 26, 1997;
revised manuscript received April 30, 1998,
accepted May 15, 1998.
Address for correspondence: Jerald L. Cohen, MD, Cardiology Section, New Jersey VA Medical Center, 385 Tremont Avenue, East Orange, New Jersey 07018
Objectives. The echocardiographic contrast-enhancing effects and safety profile of ALBUNEX (a suspension of air-filled albumin microspheres) were compared with the new contrast agent OPTISON (formerly FS069: a suspension of albumin microspheres containing the gas perfluoropropane) in 203 patients with inadequate noncontrast echocardiograms.
Background. The efficacy of ALBUNEX has been limited by its short duration of action. By using perfluoropropane instead of air within the microsphere, its duration of action is increased.
Methods. Each patient received ALBUNEX (0.8 and 0.22 mL/kg) and OPTISON (0.2, 0.5, 3.0, and 5.0 mL) on separate days a minimum of 48 hours apart. Echocardiograms were evaluated for increase in left ventricular (LV) endocardial border length, degree of LV opacification, number of LV endocardial border segments visualized, conversion from a nondiagnostic to a diagnostic echocardiogram, and duration of contrast enhancement. A thorough safety evaluation was conducted.
Results. Compared with ALBUNEX, OPTISON more significantly improved every measure of contrast enhancement. OPTISON increased well-visualized LV endocardial border length by 6.0 ± 5.1, 6.9 ± 5.4, 7.5 ± 4.7, and 7.6 ± 4.8 cm, respectively, for each of the four doses, compared with only 2.2 ± 4.5 and 3.4 ± 4.6 cm, respectively, for the two ALBUNEX doses (p < 0.001). 100% LV opacification was achieved in 61%, 73%, 87%, and 87% of the patients with the four doses of OPTISON, but in only 16% and 36% of the patients with the two ALBUNEX doses (p < 0.001). Conversion of nondiagnostic to diagnostic echocardiograms with contrast occurred in 74% of patients with the optimal dose of OPTISON (3.0 mL) compared with only 26% with the optimal dose of ALBUNEX (0.22 mL/kg) (p < 0.001). The duration of contrast effect was also significantly greater with OPTISON than with ALBUNEX. In a subset of patients with potentially poor transpulmonary transit of contrast (patients with chronic lung disease or dilated cardiomyopathy), OPTISON more significantly improved the same measures of contrast enhancement compared with ALBUNEX and did so to the same extent as in the overall population. Side effects were similar and transient with the two agents.
Conclusion. OPTISON appears to be a safe, well-tolerated echocardiographic contrast agent that is superior to ALBUNEX.
|
Abbreviations and Acronyms
| | ECG | = electrocardiogram | | LV | = left ventricular |
|
This article has been cited by other articles:
|
|
|
|
 
R. Senior, H. Becher, M. Monaghan, L. Agati, J. Zamorano, J. L. Vanoverschelde, and P. Nihoyannopoulos
Contrast echocardiography: evidence-based recommendations by European Association of Echocardiography
Eur J Echocardiogr,
March 1, 2009;
10(2):
194 - 212.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Dolan, S. S. Gala, S. Dodla, S. S. Abdelmoneim, F. Xie, D. Cloutier, M. Bierig, S. L. Mulvagh, T. R. Porter, and A. J. Labovitz
Safety and efficacy of commercially available ultrasound contrast agents for rest and stress echocardiography a multicenter experience.
J. Am. Coll. Cardiol.,
January 6, 2009;
53(1):
32 - 38.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. L. Main, J. H. Goldman, and P. A. Grayburn
Thinking Outside the "Box" The Ultrasound Contrast Controversy
J. Am. Coll. Cardiol.,
December 18, 2007;
50(25):
2434 - 2437.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Olszewski, J. Timperley, S. Cezary, M. Monaghan, P. Nihoyannopoulis, R. Senior, and H. Becher
The clinical applications of contrast echocardiography
Eur J Echocardiogr,
June 1, 2007;
8(3):
s13 - s23.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Geisler, H.C. Rost, P.S. Wild, and R. Zotz
Freehand three-dimensional assessment of left ventricular volumes and ejection fraction with ultrasound contrast agent LK565
Eur J Echocardiogr,
January 1, 2007;
8(1):
19 - 29.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. A. Whalley, G. D. Gamble, H. J. Walsh, N. Sharpe, and R. N. Doughty
Quantitative evaluation of regional endocardial visualisation with second harmonic imaging and contrast left ventricular opacification in heart failure patients
Eur J Echocardiogr,
March 1, 2005;
6(2):
134 - 143.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H Becher, J Chambers, K Fox, R Jones, G J Leech, N Masani, M Monaghan, R More, P Nihoyannopoulos, H Rimington, et al.
BSE procedure guidelines for the clinical application of stress echocardiography, recommendations for performance and interpretation of stress echocardiography: A report of the British Society of Echocardiography Policy Committee
Heart,
December 1, 2004;
90(suppl_6):
vi23 - vi30.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Kono, S. P. Pinnell, C. B. Sirlin, S. R. Sparks, B. Georgy, W. Wong, and R. F. Mattrey
Carotid Arteries: Contrast-enhanced US Angiography--Preliminary Clinical Experience
Radiology,
February 1, 2004;
230(2):
561 - 568.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. A. Whalley, G. D. Gamble, H. J. Walsh, S. P. Wright, S. Agewall, N. Sharpe, and R. N. Doughty
Effect of tissue harmonic imaging and contrast upon between observer and test-retest reproducibility of left ventricular ejection fraction measurement in patients with heart failure
Eur J Heart Fail,
January 1, 2004;
6(1):
85 - 93.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Fox, V. Formanek, A. Friedrich, and S. K. Shernan
Intraoperative Echocardiography
Card. Surg. Adult,
January 1, 2003;
2(2003):
283 - 314.
[Full Text]
|
|
|
|
|
|
|
J. F. Zachary, S. A. Hartleben, L. A. Frizzell, and W. D. O'Brien Jr
Arrhythmias in Rat Hearts Exposed to Pulsed Ultrasound After Intravenous Injection of a Contrast Agent
J. Ultrasound Med.,
December 1, 2002;
21(12):
1347 - 1356.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Becher, K. Tiemann, S. Kuntz-Hehner, H. Omran, and T. Schlosser
Diagnostic impact of contrast echocardiography for assessment of left ventricular function and myocardial perfusion in patients with coronary artery disease
Eur. Heart J. Suppl.,
March 1, 2002;
4(suppl_C):
C12 - C21.
[Abstract]
[PDF]
|
|
|
|
|
|
|
T. T. Nguyen, M. R. Dhond, R. Sabapathy, and W. J. Bommer
Contrast Microbubbles Improve Diagnostic Yield in ICU Patients With Poor Echocardiographic Windows
Chest,
October 1, 2001;
120(4):
1287 - 1292.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. L. Thomson, A.-J. Basmadjian, A. J. Rainbird, M. Razavi, J.-F. Avierinos, P. A. Pellikka, K. R. Bailey, J. F. Breen, and M. Enriquez-Sarano
Contrast echocardiography improves the accuracy and reproducibility of left ventricular remodeling measurements: A prospective, randomly assigned, blinded study
J. Am. Coll. Cardiol.,
September 1, 2001;
38(3):
867 - 875.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kuntz-Hehner, J. Goenechea, C. Pohl, T. Schlosser, C. Veltmann, C. Lentz, S. Lohmaier, A. Ehlgen, H. Omran, H. Becher, et al.
Continuous-Infusion Contrast-enhanced US: In Vitro Studies of Infusion Techniques with Different Contrast Agents
Radiology,
September 1, 2001;
220(3):
647 - 654.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Mor-Avi, E. G. Caiani, K. A. Collins, C. E. Korcarz, J. E. Bednarz, and R. M. Lang
Combined Assessment of Myocardial Perfusion and Regional Left Ventricular Function by Analysis of Contrast-Enhanced Power Modulation Images
Circulation,
July 17, 2001;
104(3):
352 - 357.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J K Blomley, J. C Cooke, E. C Unger, M. J Monaghan, and D. O Cosgrove
Science, medicine, and the future: Microbubble contrast agents: a new era in ultrasound
BMJ,
May 19, 2001;
322(7296):
1222 - 1225.
[Full Text]
|
|
|
|
|
|
|
K. Suehiro, S. Takuma, C. Cardinale, T. Hozumi, J. Shimizu, H. Yano, M. R. Di Tullio, J. Wang, C. R. Smith, D. Burkhoff, et al.
Assessment of segmental wall motion abnormalities using contrast two-dimensional echocardiography in awake mice
Am J Physiol Heart Circ Physiol,
April 1, 2001;
280(4):
H1729 - H1735.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Poldermans, J. J. Bax, A. Elhendy, F. Sozzi, E. Boersma, I. R. Thomson, and L. J. Jordaens
Long-term Prognostic Value of Dobutamine Stress Echocardiography in Patients With Atrial Fibrillation
Chest,
January 1, 2001;
119(1):
144 - 149.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Mychaskiw II, A. E. Badr, R. Tibbs, B. R. Clower, and J. H. Zhang
Optison (FS069) Disrupts the Blood-Brain Barrier in Rats
Anesth. Analg.,
October 1, 2000;
91(4):
798 - 803.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. K. Heinle, J. Noblin, P. Goree-Best, A. Mello, G. Ravad, S. Mull, P. Mammen, and P. A. Grayburn
Assessment of Myocardial Perfusion by Harmonic Power Doppler Imaging at Rest and During Adenosine Stress : Comparison With 99mTc-Sestamibi SPECT Imaging
Circulation,
July 4, 2000;
102(1):
55 - 60.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Bierig, J. V. Chapman, C. Newman, and V. Zuck
Contrast Echocardiography in Clinical Practice: Integration of Contrast Echocardiography
Journal of Diagnostic Medical Sonography,
May 1, 2000;
16(3):
97 - 102.
[Abstract]
[PDF]
|
|
|
|
|
|
|
W. A. Zoghbi and E. Barasch
Dobutamine MRI: : A Serious Contender in Pharmacological Stress Imaging?
Circulation,
February 16, 1999;
99(6):
730 - 732.
[Full Text]
[PDF]
|
|
|
|
